rs695872

Variant summary

Our verdict is Benign. The variant received -15 ACMG points: 0P and 15B. BP4_StrongBP6_ModerateBP7BA1

The ENST00000550104.5(ATXN2):​c.390C>T​(p.Arg130Arg) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.736 in 1,245,850 control chromosomes in the GnomAD database, including 351,651 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★).

Frequency

Genomes: 𝑓 0.61 ( 31878 hom., cov: 29)
Exomes 𝑓: 0.75 ( 319773 hom. )

Consequence

ATXN2
ENST00000550104.5 synonymous

Scores

2

Clinical Significance

Benign criteria provided, single submitter B:4

Conservation

PhyloP100: -0.132

Publications

23 publications found
Variant links:
Genes affected
ATXN2 (HGNC:10555): (ataxin 2) This gene belongs to a group of genes that is associated with microsatellite-expansion diseases, a class of neurological and neuromuscular disorders caused by expansion of short stretches of repetitive DNA. The protein encoded by this gene has two globular domains near the N-terminus, one of which contains a clathrin-mediated trans-Golgi signal and an endoplasmic reticulum exit signal. The encoded cytoplasmic protein localizes to the endoplasmic reticulum and plasma membrane, is involved in endocytosis, and modulates mTOR signals, modifying ribosomal translation and mitochondrial function. The N-terminal region of the protein contains a polyglutamine tract of 14-31 residues that can be expanded in the pathogenic state to 32-200 residues. Intermediate length expansions of this tract increase susceptibility to amyotrophic lateral sclerosis, while long expansions of this tract result in spinocerebellar ataxia-2, an autosomal-dominantly inherited, neurodegenerative disorder. Genome-wide association studies indicate that loss-of-function mutations in this gene may be associated with susceptibility to type I diabetes, obesity and hypertension. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2016]
ATXN2-AS (HGNC:51838): (ATXN2 antisense RNA)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -15 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.52).
BP6
Variant 12-111599125-G-A is Benign according to our data. Variant chr12-111599125-G-A is described in ClinVar as Benign. ClinVar VariationId is 128508.Status of the report is criteria_provided_single_submitter, 1 stars.
BP7
Synonymous conserved (PhyloP=-0.132 with no splicing effect.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.779 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ATXN2NM_001372574.1 linkc.-91C>T 5_prime_UTR_variant Exon 1 of 25 ENST00000673436.1 NP_001359503.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ATXN2ENST00000673436.1 linkc.-91C>T 5_prime_UTR_variant Exon 1 of 25 NM_001372574.1 ENSP00000500925.1 A0A5F9ZI57

Frequencies

GnomAD3 genomes
AF:
0.609
AC:
91398
AN:
150064
Hom.:
31888
Cov.:
29
show subpopulations
Gnomad AFR
AF:
0.310
Gnomad AMI
AF:
0.853
Gnomad AMR
AF:
0.580
Gnomad ASJ
AF:
0.870
Gnomad EAS
AF:
0.0934
Gnomad SAS
AF:
0.630
Gnomad FIN
AF:
0.823
Gnomad MID
AF:
0.619
Gnomad NFE
AF:
0.785
Gnomad OTH
AF:
0.615
GnomAD2 exomes
AF:
0.787
AC:
2080
AN:
2644
AF XY:
0.786
show subpopulations
Gnomad AFR exome
AF:
0.438
Gnomad AMR exome
AF:
0.671
Gnomad ASJ exome
AF:
0.919
Gnomad FIN exome
AF:
0.845
Gnomad NFE exome
AF:
0.810
Gnomad OTH exome
AF:
0.776
GnomAD4 exome
AF:
0.754
AC:
825798
AN:
1095676
Hom.:
319773
Cov.:
69
AF XY:
0.756
AC XY:
395318
AN XY:
522780
show subpopulations
African (AFR)
AF:
0.296
AC:
6613
AN:
22326
American (AMR)
AF:
0.573
AC:
4706
AN:
8208
Ashkenazi Jewish (ASJ)
AF:
0.874
AC:
12389
AN:
14176
East Asian (EAS)
AF:
0.139
AC:
3541
AN:
25484
South Asian (SAS)
AF:
0.671
AC:
16656
AN:
24824
European-Finnish (FIN)
AF:
0.815
AC:
17989
AN:
22060
Middle Eastern (MID)
AF:
0.643
AC:
1890
AN:
2940
European-Non Finnish (NFE)
AF:
0.785
AC:
731568
AN:
931924
Other (OTH)
AF:
0.696
AC:
30446
AN:
43734
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.493
Heterozygous variant carriers
0
10980
21959
32939
43918
54898
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
19556
39112
58668
78224
97780
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.609
AC:
91402
AN:
150174
Hom.:
31878
Cov.:
29
AF XY:
0.609
AC XY:
44678
AN XY:
73366
show subpopulations
African (AFR)
AF:
0.309
AC:
12687
AN:
40994
American (AMR)
AF:
0.579
AC:
8758
AN:
15122
Ashkenazi Jewish (ASJ)
AF:
0.870
AC:
3005
AN:
3456
East Asian (EAS)
AF:
0.0939
AC:
470
AN:
5006
South Asian (SAS)
AF:
0.630
AC:
3008
AN:
4774
European-Finnish (FIN)
AF:
0.823
AC:
8422
AN:
10228
Middle Eastern (MID)
AF:
0.621
AC:
180
AN:
290
European-Non Finnish (NFE)
AF:
0.785
AC:
52812
AN:
67312
Other (OTH)
AF:
0.618
AC:
1294
AN:
2094
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.506
Heterozygous variant carriers
0
1392
2784
4177
5569
6961
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
726
1452
2178
2904
3630
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.685
Hom.:
4673
Bravo
AF:
0.571
Asia WGS
AF:
0.413
AC:
1382
AN:
3344

ClinVar

Significance: Benign
Submissions summary: Benign:4
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not specified Benign:2
-
Genetic Services Laboratory, University of Chicago
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed. -

-
Clinical Genetics, Academic Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Spinocerebellar ataxia type 2 Benign:1
Oct 06, 2015
Genome Diagnostics Laboratory, Amsterdam University Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

not provided Benign:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.52
CADD
Benign
17
DANN
Benign
0.93
PhyloP100
-0.13
PromoterAI
-0.030
Neutral
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs695872; hg19: chr12-112036929; COSMIC: COSV108225761; COSMIC: COSV108225761; API